The interim NHS People Plan, published on 3 June 2019, puts the workforce at the heart of the National Health Service and will ensure we have the staff needed to deliver high quality care. A final People Plan will be published soon after the conclusion of the 2019 Spending Review.<\/p>
Phase 1 of the Cancer Workforce Plan for England, published in December 2017 by Health Education England (HEE), set out plans to expand capacity and skills in the cancer workforce, including targeting additional training support for seven priority professions which are key to cancer prevention, diagnosis and treatment, such as clinical radiology, histopathology, oncology and diagnostic and therapeutic radiography.<\/p>
HEE will now work with NHS England and NHS Improvement to understand the longer-term workforce implications of further development of cancer services. This work will inform the final People Plan.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2019-08-05", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-08-05T11:30:43.603Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer: Health Services"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, when a long-term workforce plan which sets out the number of staff required to meet the current and future needs of cancer patients will be published.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"} } , "tablingMemberConstituency" : {"_value" : "Denton and Reddish"} , "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"} ], "uin" : "280964"} , {"_about" : "http://data.parliament.uk/resources/1141282", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1141282/answer", "answerText" : {"_value" : "
Public Health England (PHE) has published a series of reports on electronic cigarettes including the effects of vaping on health. The reports are available to view at the following link:<\/p>
https://www.gov.uk/government/collections/e-cigarettes-and-vaping-policy-regulation-and-guidance<\/a><\/p> While nicotine can contribute to raised blood pressure and cardiovascular risk, it is tar and carbon monoxide, which are the major sources of cardiovascular risk in cigarette smoke, producing nicotine vapour from a solution rather than by burning tobacco means that electronic cigarette vapour is free from almost all the toxic chemicals that accompany nicotine in cigarette smoke.<\/p> The Office for National Statistics has recorded the numbers of people using e-cigarettes since 2014 and the combined number of people using e-cigarettes and smoking has not increased since then. The proportion of people who smoke has decreased substantially in the same period.<\/p> PHE encourages people who both vape and smoke to stop smoking completely, because this greatly reduces health risks.<\/p> <\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
}
, "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
, "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
, "dateOfAnswer" : {"_value" : "2019-08-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-08-05T11:25:52.907Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Electronic Cigarettes: Health Hazards"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the increased numbers of people vaping on (a) nicotine addiction, (b) incidences of increased blood pressure and (c) heart attack rates.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4498", "label" : {"_value" : "Biography information for Mr Ranil Jayawardena"}
}
, "tablingMemberConstituency" : {"_value" : "North East Hampshire"}
, "tablingMemberPrinted" : [{"_value" : "Mr Ranil Jayawardena"}
], "uin" : "281030"}
, {"_about" : "http://data.parliament.uk/resources/1141283", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1141283/answer", "answerText" : {"_value" : " The Government believes in proportionate regulation of e-cigarettes, recognising that they are not risk-free. Through the European Union Tobacco Products Directive 2014/40/EU (TPD), transposed into United Kingdom law by the UK Tobacco and Related Products Regulations 2016 (TRPR), we have introduced measures to regulate e-cigarettes. These measures reduce the risk of harm to children, protect against any risk of renormalisation of tobacco use, provide assurance on relative safety for users, and give businesses legal certainty. This has enabled the UK to implement appropriate standards for products whilst allowing smokers to move to e-cigarettes should they wish.<\/p> <\/p> The Government has made a commitment to review the TRPR by May 2021 to consider its regulatory impact. In addition, as announced in the Tobacco Control Plan the Government will review where the UK\u2019s exit from the European Union offers us opportunities to re-appraise current regulation to ensure this continues to protect the nation\u2019s health.<\/p> The Government has no plans to introduce legislative proposals to ban e-cigarettes, e-cigarette shops or smoking on National Health Service property.<\/p> We continue to support the implementation of smokefree policies across all hospitals in England. The Government\u2019s tobacco control plan for England published in July 2017 reiterates our ambition to achieve smokefree mental health services and NHS estate by 2019/20. The NHS Long Term Plan, published in January 2019, further supports the creation of a Smokefree NHS with the commitment to offering NHS-funded tobacco treatment services to all patients who smoke.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
}
, "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
, "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
, "dateOfAnswer" : {"_value" : "2019-08-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "281032"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-08-05T11:29:19.74Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Electronic Cigarettes"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will bring forward legislative proposals to ban e-cigarettes wherever the smoking ban is in place. .", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4498", "label" : {"_value" : "Biography information for Mr Ranil Jayawardena"}
}
, "tablingMemberConstituency" : {"_value" : "North East Hampshire"}
, "tablingMemberPrinted" : [{"_value" : "Mr Ranil Jayawardena"}
], "uin" : "281031"}
, {"_about" : "http://data.parliament.uk/resources/1141284", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1141284/answer", "answerText" : {"_value" : " The Government believes in proportionate regulation of e-cigarettes, recognising that they are not risk-free. Through the European Union Tobacco Products Directive 2014/40/EU (TPD), transposed into United Kingdom law by the UK Tobacco and Related Products Regulations 2016 (TRPR), we have introduced measures to regulate e-cigarettes. These measures reduce the risk of harm to children, protect against any risk of renormalisation of tobacco use, provide assurance on relative safety for users, and give businesses legal certainty. This has enabled the UK to implement appropriate standards for products whilst allowing smokers to move to e-cigarettes should they wish.<\/p> <\/p> The Government has made a commitment to review the TRPR by May 2021 to consider its regulatory impact. In addition, as announced in the Tobacco Control Plan the Government will review where the UK\u2019s exit from the European Union offers us opportunities to re-appraise current regulation to ensure this continues to protect the nation\u2019s health.<\/p> The Government has no plans to introduce legislative proposals to ban e-cigarettes, e-cigarette shops or smoking on National Health Service property.<\/p> We continue to support the implementation of smokefree policies across all hospitals in England. The Government\u2019s tobacco control plan for England published in July 2017 reiterates our ambition to achieve smokefree mental health services and NHS estate by 2019/20. The NHS Long Term Plan, published in January 2019, further supports the creation of a Smokefree NHS with the commitment to offering NHS-funded tobacco treatment services to all patients who smoke.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
}
, "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
, "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
, "dateOfAnswer" : {"_value" : "2019-08-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "281031"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-08-05T11:29:19.787Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Hospitals: Electronic Cigarettes"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will bring forward legislative proposals to ban (a) e-cigarette shops and (b) smoking on NHS hospital property.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4498", "label" : {"_value" : "Biography information for Mr Ranil Jayawardena"}
}
, "tablingMemberConstituency" : {"_value" : "North East Hampshire"}
, "tablingMemberPrinted" : [{"_value" : "Mr Ranil Jayawardena"}
], "uin" : "281032"}
, {"_about" : "http://data.parliament.uk/resources/1141336", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1141336/answer", "answerText" : {"_value" : " The Government is not actively looking to increase the number of community pharmacies in England.<\/p> Applications to provide National Health Service pharmaceutical services continue to be determined by NHS England and NHS Improvement, informed by the local pharmaceutical needs assessment, which outlines the level of NHS pharmaceutical services provision in a given area, including if there are any gaps or unmet needs.<\/p> In England, access to NHS pharmaceutical services is good. There are over 11,500 community pharmacies, which is 12% more than a decade ago. This coverage means that 80% of the population live within 20 minutes walking distance of a community pharmacy, with more pharmacies in the most deprived areas.<\/p> Maintaining access to NHS pharmaceutical services remains an important priority for the Government. We will continue to maintain the good level of access we have in England through the Pharmacy Access Scheme, which provides additional financial support to pharmacies in areas where there are fewer pharmacies.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
}
, "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
, "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
, "dateOfAnswer" : {"_value" : "2019-08-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-08-05T11:27:19.42Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pharmacy"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the number of community pharmacies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4679", "label" : {"_value" : "Biography information for Neil O'Brien"}
}
, "tablingMemberConstituency" : {"_value" : "Harborough"}
, "tablingMemberPrinted" : [{"_value" : "Neil O'Brien"}
], "uin" : "281058"}
, {"_about" : "http://data.parliament.uk/resources/1141356", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1141356/answer", "answerText" : {"_value" : " Decisions on whether individual medicines are suitable for assessment by the National Institute for Health and Care Excellence (NICE), and whether they meet the criteria for the highly specialised technologies programme, are taken through an established topic selection process.<\/p> The process is overseen by NICE and includes consideration against published criteria by a topic selection panel and engagement with stakeholders. Although NHS England, NHS Improvement and the Department provide input and are part of this panel, the decision-making process is led by NICE. Kuvan for the treatment of phenylketonuria was last considered by the topic selection panel on 15 February 2019.<\/p> In the absence of guidance from NICE, it is for National Health Service organisations and healthcare professionals to make decisions on whether to fund Kuvan on the basis of an assessment of the available evidence. Treatment for patients with phenylketonuria who are not receiving Kuvan or for who Kuvan is not effective includes dietary protein restriction combined with dietary supplements.<\/p> <\/p> <\/p> <\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
}
, "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
, "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
, "dateOfAnswer" : {"_value" : "2019-08-06", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-08-06T14:36:02.507Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Sapropterin"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment his Department has made of whether Kuvan should be assessed through NICE's highly-specialised technology appraisal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1438", "label" : {"_value" : "Biography information for Mr Kevan Jones"}
}
, "tablingMemberConstituency" : {"_value" : "North Durham"}
, "tablingMemberPrinted" : [{"_value" : "Mr Kevan Jones"}
], "uin" : "280943"}
, {"_about" : "http://data.parliament.uk/resources/1141362", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1141362/answer", "answerText" : {"_value" : " While post vaccine rash and fever is generally mild, distinguishing from wild-type measles is not based on clinical examination, rather it is based on a combination of laboratory analysis, information on the timing of vaccine and epidemiological information. The national measles guidelines describe the management and investigation of suspected cases of measles, and is available to view at the following link:<\/p> https://www.gov.uk/government/publications/national-measles-guidelines<\/a><\/p> Statistics on confirmed measles cases are reported by vaccination status and are available at the following link:<\/p> https://www.gov.uk/government/publications/measles-mumps-and-rubella-lab-confirmed-cases-in-england-2019<\/a><\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
}
, "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
, "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
, "dateOfAnswer" : {"_value" : "2019-08-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "280996"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-08-05T11:32:33.127Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Measles"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what guidance his Department has published on distinguishing between rashes caused by the measles vaccine and those arising from the wild strain of measles.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1522", "label" : {"_value" : "Biography information for Adam Holloway"}
}
, "tablingMemberConstituency" : {"_value" : "Gravesham"}
, "tablingMemberPrinted" : [{"_value" : "Adam Holloway"}
], "uin" : "280995"}
, {"_about" : "http://data.parliament.uk/resources/1141363", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1141363/answer", "answerText" : {"_value" : " While post vaccine rash and fever is generally mild, distinguishing from wild-type measles is not based on clinical examination, rather it is based on a combination of laboratory analysis, information on the timing of vaccine and epidemiological information. The national measles guidelines describe the management and investigation of suspected cases of measles, and is available to view at the following link:<\/p> https://www.gov.uk/government/publications/national-measles-guidelines<\/a><\/p> Statistics on confirmed measles cases are reported by vaccination status and are available at the following link:<\/p> https://www.gov.uk/government/publications/measles-mumps-and-rubella-lab-confirmed-cases-in-england-2019<\/a><\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
}
, "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
, "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
, "dateOfAnswer" : {"_value" : "2019-08-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "280995"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-08-05T11:32:33.183Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Measles"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that statistics on the infection rate for measles do not include people who have received the live measles vaccine and contracted a measles-like rash and fever.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1522", "label" : {"_value" : "Biography information for Adam Holloway"}
}
, "tablingMemberConstituency" : {"_value" : "Gravesham"}
, "tablingMemberPrinted" : [{"_value" : "Adam Holloway"}
], "uin" : "280996"}
, {"_about" : "http://data.parliament.uk/resources/1141364", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1141364/answer", "answerText" : {"_value" : " The safety of all the United Kingdom\u2019s vaccination programmes is of paramount importance. Any serious side effects are extremely rare, and the large majority of side effects are mild and transient, such as sore arms, headaches and tiredness. We would recommend that all eligible children are vaccinated, as any potential risk of side effects is far outweighed by the benefits of vaccination.<\/p> Healthcare professionals have access to a range of materials, such as \u2018Immunisation against infectious disease: the green book\u2019 and Patient Group Directions to support their decision-making in the case of any suspected adverse effects.<\/p> The Medicines and Healthcare products Regulatory Agency (MHRA) operates the \u2018Yellow Card Scheme\u2019, which is vital in helping the MHRA monitor the safety of all healthcare products in the UK. This system allows for reporting of any potential adverse events for all medicines, including vaccines, with guidance for healthcare professionals, patients and the public on how to use the scheme.<\/p> In addition, Public Health England (PHE) offers diagnostic services for suspected cases of encephalitis, which is a notifiable condition. Under statutory duty, cases must be reported by healthcare professionals to PHE\u2019s local Health Protection Teams. This can be viewed at the following link:<\/p>